View Complaint
Retainer Agreement
info@rosenlegal.com

Solid Biosciences shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

Solid Biosciences Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Solid Biosciences Inc. (NASDAQ: SLDB): (1) in Solid Biosciences’ initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive. The lawsuit seeks to recover investor losses.

If you purchased Solid Biosciences securities during this period and would like to join the action, please click "Join This Class Action" above. 

Press Release

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Solid Biosciences Inc. – SLDB

New York, N.Y., March 27, 2018. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Solid Biosciences Inc. (NASDAQ: SLDB): (1) in Solid Biosciences’ initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Solid Biosciences investors under the federal securities laws.

To join the Solid Biosciences class action, go to http://rosenlegal.com/cases-1309.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or zhalper@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

A class action has already been filed. According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Solid Biosciences’ lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) as a result, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading. When the true details entered the market, Solid Biosciences’ share price fell $18.19 per share in the aggregate, damaging investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1309.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Zachary Halper, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      zhalper@rosenlegal.com
      www.rosenlegal.com